Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy
PHASE2CompletedINTERVENTIONAL
Enrollment
23
Participants
Timeline
Start Date
January 11, 2018
Primary Completion Date
May 1, 2023
Study Completion Date
May 1, 2023
Conditions
Stage I Bladder Cancer AJCC v8Stage II Bladder Cancer AJCC v8Stage III Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8Stage IIIB Bladder Cancer AJCC v8
Interventions
BIOLOGICAL
Pembrolizumab
Given IV
Trial Locations (1)
77030
M D Anderson Cancer Center, Houston
All Listed Sponsors
collaborator
National Cancer Institute (NCI)
NIH
lead
M.D. Anderson Cancer Center
OTHER
NCT03319745 - Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy | Biotech Hunter | Biotech Hunter